This article is part of our special focus on "traditional" pharma: The Small Molecule Manufacturer (read more here). You can find more articles from The Small Manufacturer here.
- Catalent has completed its purchase of a Bristol-Myer-Squibb site in Anangi, Italy. The site, which has capabilities to support product launches for oral solids, as well as the production of primary and secondary packaging solutions will help reduce “time-to-market, simplify tech transfers, and minimize program risk” across Catalent’s European network. Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.
- Alcami has announced the sale of its preclinical and early stage API facility in Weert, the Netherlands, to MercachemSyncom. The company has been taking a number of steps recently to improve productivity across its sites. Despite selling the Weert-based site, the company says it will retain its European sales and business development team.
- Sanofi’s Chief Executive Officer, Paul Hudson, announced plans to reduce the company’s reliance on CMOs to improve cost savings. The company hopes to find €2 billion dollars by 2022 and predicts that cutting down on CMO use will contribute €500 million (the rest is expected to come from reduced spending on deprioritized businesses and general procurement savings). The company also explained that it would be letting go of its “low-selling” product families, leaving them with 100 by 2025.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
